FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626534878> ?p ?o ?g. }

• W2626534878 endingPage "537" @default.
• W2626534878 startingPage "524" @default.
• W2626534878 abstract "IVA337 is a pan‐peroxisome proliferator‐activated receptor (PPAR) agonist with moderate and well‐balanced activity on the three PPAR isoforms (α, γ, δ). PPARs are regulators of lipid metabolism, inflammation, insulin resistance, and fibrogenesis. Different single or dual PPAR agonists have been investigated for their therapeutic potential in nonalcoholic steatohepatitis (NASH), a chronic liver condition in which steatosis coexists with necroinflammation, potentially leading to liver fibrosis and cirrhosis. Clinical results have demonstrated variable improvements of histologically assessed hepatic lesions depending on the profile of the tested drug, suggesting that concomitant activation of the three PPAR isoforms would translate into a more substantial therapeutic outcome in patients with NASH. We investigated the effects of IVA337 on several preclinical models reproducing the main metabolic and hepatic features associated with NASH. These models comprised a diet‐induced obesity model (high‐fat/high‐sucrose diet); a methionine‐ and choline‐deficient diet; the foz/foz model; the CCl 4 ‐induced liver fibrosis model (prophylactic and therapeutic) and human primary hepatic stellate cells. IVA337 normalized insulin sensitivity while controlling body weight gain, adiposity index, and serum triglyceride increases; it decreased liver steatosis, inflammation, and ballooning. IVA337 demonstrated preventive and curative effects on fibrosis in the CCl 4 model and inhibited proliferation and activation of human hepatic stellate cells, the key cells driving liver fibrogenesis in NASH. Moreover, IVA337 inhibited the expression of (pro)fibrotic and inflammasome genes while increasing the expression of β‐oxidation‐related and fatty acid desaturation‐related genes in both the methionine‐ and choline‐deficient diet and the foz/foz model. For all models, IVA337 displayed an antifibrotic efficacy superior to selective PPARα, PPARδ, or PPARγ agonists. Conclusion : The therapeutic potential of IVA337 for the treatment of patients with NASH is supported by our data. ( Hepatology Communications 2017;1:524–537)" @default.
• W2626534878 created "2017-06-23" @default.
• W2626534878 creator A5018537505 @default.
• W2626534878 creator A5024172203 @default.
• W2626534878 creator A5039906991 @default.
• W2626534878 creator A5040303014 @default.
• W2626534878 creator A5045325079 @default.
• W2626534878 creator A5045546704 @default.
• W2626534878 creator A5045906192 @default.
• W2626534878 creator A5049270330 @default.
• W2626534878 creator A5051932479 @default.
• W2626534878 creator A5052593818 @default.
• W2626534878 creator A5055388507 @default.
• W2626534878 creator A5063893824 @default.
• W2626534878 creator A5069516720 @default.
• W2626534878 creator A5070305851 @default.
• W2626534878 creator A5070970519 @default.
• W2626534878 creator A5074569894 @default.
• W2626534878 creator A5082471459 @default.
• W2626534878 creator A5087712428 @default.
• W2626534878 creator A5087996382 @default.
• W2626534878 creator A5089895034 @default.
• W2626534878 date "2017-06-19" @default.
• W2626534878 modified "2023-10-15" @default.
• W2626534878 title "The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis" @default.
• W2626534878 cites W1963533730 @default.
• W2626534878 cites W1977036235 @default.
• W2626534878 cites W1977508200 @default.
• W2626534878 cites W1990476352 @default.
• W2626534878 cites W2001940599 @default.
• W2626534878 cites W2002266832 @default.
• W2626534878 cites W2007582789 @default.
• W2626534878 cites W2008777641 @default.
• W2626534878 cites W2015643123 @default.
• W2626534878 cites W2022174018 @default.
• W2626534878 cites W2031469397 @default.
• W2626534878 cites W2033112320 @default.
• W2626534878 cites W2038654926 @default.
• W2626534878 cites W2049054564 @default.
• W2626534878 cites W2062812115 @default.
• W2626534878 cites W2063065419 @default.
• W2626534878 cites W2072234373 @default.
• W2626534878 cites W2078434599 @default.
• W2626534878 cites W2080361134 @default.
• W2626534878 cites W2082702559 @default.
• W2626534878 cites W2083685463 @default.
• W2626534878 cites W2086022508 @default.
• W2626534878 cites W2091296342 @default.
• W2626534878 cites W2092700213 @default.
• W2626534878 cites W2093025818 @default.
• W2626534878 cites W2099966991 @default.
• W2626534878 cites W2102224211 @default.
• W2626534878 cites W2103116278 @default.
• W2626534878 cites W2105900654 @default.
• W2626534878 cites W2107683043 @default.
• W2626534878 cites W2113511371 @default.
• W2626534878 cites W2124688365 @default.
• W2626534878 cites W2128557965 @default.
• W2626534878 cites W2131483137 @default.
• W2626534878 cites W2139318977 @default.
• W2626534878 cites W2141314779 @default.
• W2626534878 cites W2142179862 @default.
• W2626534878 cites W2145725957 @default.
• W2626534878 cites W2150702412 @default.
• W2626534878 cites W2163207725 @default.
• W2626534878 cites W2170075604 @default.
• W2626534878 cites W2171697576 @default.
• W2626534878 cites W2253420963 @default.
• W2626534878 cites W2338295645 @default.
• W2626534878 cites W2346880536 @default.
• W2626534878 cites W2418112989 @default.
• W2626534878 cites W2470709274 @default.
• W2626534878 cites W841481485 @default.
• W2626534878 doi "https://doi.org/10.1002/hep4.1057" @default.
• W2626534878 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5678909" @default.
• W2626534878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29404476" @default.
• W2626534878 hasPublicationYear "2017" @default.
• W2626534878 type Work @default.
• W2626534878 sameAs 2626534878 @default.
• W2626534878 citedByCount "87" @default.
• W2626534878 countsByYear W26265348782017 @default.
• W2626534878 countsByYear W26265348782018 @default.
• W2626534878 countsByYear W26265348782019 @default.
• W2626534878 countsByYear W26265348782020 @default.
• W2626534878 countsByYear W26265348782021 @default.
• W2626534878 countsByYear W26265348782022 @default.
• W2626534878 countsByYear W26265348782023 @default.
• W2626534878 crossrefType "journal-article" @default.
• W2626534878 hasAuthorship W2626534878A5018537505 @default.
• W2626534878 hasAuthorship W2626534878A5024172203 @default.
• W2626534878 hasAuthorship W2626534878A5039906991 @default.
• W2626534878 hasAuthorship W2626534878A5040303014 @default.
• W2626534878 hasAuthorship W2626534878A5045325079 @default.
• W2626534878 hasAuthorship W2626534878A5045546704 @default.
• W2626534878 hasAuthorship W2626534878A5045906192 @default.
• W2626534878 hasAuthorship W2626534878A5049270330 @default.
• W2626534878 hasAuthorship W2626534878A5051932479 @default.
• W2626534878 hasAuthorship W2626534878A5052593818 @default.

• next